002Long-term prognostic impact of chronic total occlusion in patients with unprotected left main disease
003Impact of occlusion duration on angiographic and clinical outcomes following chronic total occlusion intervention with DES
004Endothelial progenitor cells mediate angiogenesis and coronary collateral formation in patients with chronic total coronary artery occlusion
006The role of collateral pressure index assessing collateral function and coronary haemodynamics in patients with total or nearly total occluded coronary lesions
007Operator exposure to x-ray in left and right radial access during percutaneous coronary procedures: opera study
008Radiation exposure during coronary angiography via transradial or transfemoral approaches: does operator experience matter?
009Risk of brain injury during diagnostic coronary angiography: comparison between right and left radial approach
010Incidence of neurological complications following coronary intervention: comparison of transradial and transfemoral access in 306716 procedures from the British Cardiovascular Intervention Society database
011Outcomes of radial and femoral access for coronary angiography and PCI over time: a report from the nation-wide Swedish coronary angiography and angioplasty registry
012Impact of system delay on infarct size, myocardial salvage index and left ventricular function in patients with STEMI
014In STEMI patients unsuitable for primary angioplasty, alternative management strategies do not influence 30-day and 1-year mortality
015One-year outcomes after the unrestricted use of sirolimus- versus paclitaxel-eluting stents in patients with acute myocardial infarction
016The ESTROFA-MI registry: comparison of paclitaxel-eluting stents and everolimus-eluting stents in ST-segment elevation MI. Results at 2-year follow-up
017Clinical outcomes after treating acute coronary syndrome patients with a DES: results from REWARDS-EMI (Endeavor for Myocardial Infarction) registry
018Which is better neointimal coverage between zotarolimus-eluting stents or everolimus-eluting stents?
019Three-year outcomes from the randomised comparison of a zotarolimus-eluting and an everolimus-eluting stent in the RESOLUTE all comers trial
020Safety and efficacy of everolimus- versus sirolimus-eluting stents: a meta-analysis and systemic review
021Multi center, prospective, randomised, single blind, consecutive enrollment evaluation of a novolimus-eluting coronary stent system with bioabsorbable polymer compared to a zotarolimus-eluting coronary stent system: 12-month clinical and 6-month angiographic and IVUS results: the Excella BD study
022Two-year follow-up of a polymer-free sirolimus- and probucol-eluting versus a new generation zotarolimus-eluting stents in coronary artery disease
023Twelve-month results of the REMEDEE trial: a randomised comparison of a sirolimus-eluting CD 34 antibody-coated stent versus a paclitaxel-eluting stent in patients with de-novo coronary artery stenoses
024Gender differences of vascular response following DES implantation in patients presenting with ACS: ex vivo human autopsy study
025Gender-based analysis of outcomes among patients with ACS undergoing percutaneous coronary revascularisation with DES
026Safety and efficacy of overlapping homogenous DES in patients with acute myocardial infarction: results from Korea acute myocardial infarction registry
028Long-term outcomes of 234 patients with ostial right coronary artery lesions treated with second generation DES
029Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with DES
030Occurence of very late stent thrombosis after DES implantation in daily clinical practice: 10-year follow-up of the large, prospective, single-center DESIRE registry
032First-in-man experience with a stent eluting sirolimus from an amino acid-based bioabsorbable drug carrier mounted on an integrated delivery system
033Evaluation of early healing of endothelial progenitor cell capturing sirolimus-eluting stent by optical coherence tomography: the EGO-COMBO study, first follow-up result
035Assessment of vascular response at 4, 6 and 8 months after the implantation of absorbable-coated sirolimus-eluting stents: an optical coherence tomography sub-study from the first-in-man DESSOLVE I trial
036Six and twelve-month optical coherence tomography results with the paclitaxel-eluting absorbable metal scaffold (DREAMS): BIOSOLVE-I
037Results of the drug-eluting balloon in acute STEMI (DEB-AMI) trial: a multicenter randomised comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus DES in primary PCI with 6-month angiographic, intravascular, functional and 12-month clinical outcomes
039DES with biodegradable polymer, a multivariate analysis of risk factors for early and late target lesion failure occurrence in a real-life cohort
040DES with biodegradable polymer, a multi variate analysis of risk factors for early and late stent thrombosis occurrence in a real-life cohort
041DESSOLVE I: twelve-month clinical and imaging results from the FIH trial of sirolimus-eluting absorbable polymer coronary stent system
042Six-month IVUS and 12-month clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent
044Plasmonic photothermic angioplasty with composite versatile nanoparticles and stem cells as the new revolution in interventional cardiology
047Bleeding outcomes in patients undergoing routine transradial primary angioplasty for acute myocardial infarction treated with eptifibatide and unfractionated heparin: a single center real-world experience
048Transradial primary PCI for STEMI: the balance between reperfusion time and bleeding complications
049Safety and efficacy of the radial approach for emergency angioplasty in ST-segment elevation acute myocardial infarction
050Comparison of outcomes following radial verses femoral approaches in primary or rescue PCI: analysis of the Scottish national database
0514-year follow-up after one-stage PCI of left main stenosis and infarct-related left anterior descending or circumflex arteries in STEMI patients
052Long-term outcomes following DES implantation in patients with unprotected distal trifurcation left main coronary artery stenosis: the Milan and New-Tokyo registry
053Treatment of unprotected left main with DES: 12-month outcome in the multicentric German DES.DE registry
054The ESTROFA-LM registry: comparison of paclitaxel-eluting stents and everolimus-eluting stents in left main coronary artery disease. Results at 3-year follow-up
055Outcomes following unprotected left main stem stenting with first versus new generation DES: the Milan experience
056Clinical utility of a novel torqueable balloon catheter in the treatment of complex coronary lesions
058Predictors of failure of final kissing balloon inflation after mini-crush stenting in bifurcation lesions: importance of the main vessel angle
059Increased incidence of contrast medium induced nephropathy in type 2 diabetic patients undergoing primary PCI is related to elevated serum malondialdehyde-modified low-density lipoprotein
061Is contrast-induced nephropathy following primary PCI for STEMI associated with increased long-term mortality?
062Impact of transient acute kidney injury and persistent renal dysfunction on long-term clinical outcome after PCI
063Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with STEMI undergoing primary PCI
064DES implantation is associated with lower MACE rates than bare metal stent implantation in primary PCI for STEMI
068Real-world comparison of 2-year clinical outcomes between first generation and second generation DES in Asian population
069Second versus first generation DES are associated with a better safety profile in real-world PCI: analysis of 3266 procedures from a single center prospective registry
070Legitimacy of current anatomical criteria for guidance of PCI: investigation using a novel percutaneous model of coronary artery stenosis
071Optical coherence tomography compared to IVUS in coronary lesion assessment study: OPUS-CLASS study)
072Fractional flow reserve-guided PCI optimisation: role of three-dimensional optical coherence tomography co-registration
073Quantitative optical coherence tomography tissue type imaging: validation and in vivo demonstration
074Quantitative comparison of IVUS and two generations of optical coherence tomography in non-stented and stented coronary arteries
075Novel automatic stent strut detection technique for on-site three-dimensional optical coherence tomography to complex stenting procedure
076In-hopital outcome of interventional treatment in elderly patients with ACS: Euro Heart Survey on ACS III registry
078Age is not a bar to PCI: insights from the long-term outcomes from off-site PCI in a real-world setting
079Trends and outcomes of primary percutaneous intervention in octogenarians: a four-year single center study
081Clinical outcomes in patients over 75 years old with acute myocardial infarction from the Korean acute myocardial infarction registry
083The relationship between long-term clinical outcomes and serial atheroma changes by volumetric IVUS
084Prediction and detection of inadequate coronary stent expansion: a study with IVUS and coronary computed tomography
085Vessel remodelling and peristent plaque change after DES implantation: comparison between everolimus-eluting stents and sirolimus-eluting stents
087Relationship among percent stent expansion, neointimal proliferation, and peri-stent plaque change after DES implantation
088Plaque components analysed by integrated backscatter IVUS redict major adverse cardiovascular events after primary PCI in patients with ACS
089Impact of lipid content assessed by integrated backscatter IVUS on slow or no-reflow phenomenon following the elective single everolimus-eluting stent implantation
090Serial grey-scale and radiofrequency intravascular assessment of plaque modification and vessel geometry at proximal and distal edges of bare-metal and DES
091Do plaque characteristics influence the degree of collaterals or microvascular obstruction during PCI?
093Clinical outcomes according to the presentation with cardiogenic shock in patients with left main coronary artery related acute myocardial infarction
094Role of final kissing balloon for unprotected distal left main bifurcation intervention with single stent strategy
095Stent maximal expansion capacity with current DES platforms: a critical factor for stent selection during treatment of left-main bifurcations?
096Predictors of main branch restenosis following sirolimus-eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: the Milan and New-Tokyo registry
097New generation DES experience in the treatment of unprotected left main coronary artery disease: the next registry
099Longitudinal deformation of contemporary coronary stents: an integrated analysis of clinical experience and observations from the bench
102Long-term outcome after PCI with DES compared to bare metal stents in saphenous vein graft lesions
104Safe and effective treatment of saphenous vein graft with a new generation DES: 2-year clinical outcomes
105Comparison in the 5-year outcome of pericardium and polytetrafluoroethylene-covered stents for saphenous vein graft lesions
106Prior coronary artery bypass graft patients treated with primary PCI have higher long-term adverse event rates
108Single stenting technique associated with side branch failure during PCI for complex bifurcation lesions
109Long-term results of endovascular treatment of patients with true coronary artery bifurcation lesions
110Three-year durability of crossover stenting with jail of side branch and comparison with subsequent kissing balloon technique for coronary bifurcation: sub-analysis of Taxus Japan post-market surveillance
111Immediate and long-term results of endovascular treatment of patients with multivessel coronary artery disease
112Multivessel and left main coronary artery stenting in comparison with surgical revascularisation in patients with NSTE-ACS: the MILESTONE registry
115The role of the multidisciplinary Heart Team in managing patients with coronary artery disease: structure, outcomes and reproducibility
116A randomised comparison between polymer-free paclitaxel-eluting stent and polymer-based paclitaxel-eluting stent: 2-year final clinical results
118There is no difference in long-term major adverse cardiac event rates following PCI with paclitaxel-eluting and sirolimus-eluting stents
119Comparison of angiographic and clinical outcomes among patients with sirolimus-, paclitaxel-, zotarolimus-, and everolimus-eluting stent implantation in small coronary target vessels
120Comparisons of one-year clinical outcomes of everolimus- versus sirolimus- versus paclitaxel-eluting stents in patients with acute myocardial infarction
121Safety and clinical efficacy of sideguard stent for treatment of bifurcation lesions: interim result from British multi center sideguard bifurcation registry study
123Long-term outcomes of a novel dedicated bifurcation drug-coated device for the treatment of coronary bifurcation lesions: 12-month clinical follow-up of the prospective, multicenter BIPAX clinical trial
124Four-year clinical outcomes of patients with coronary bifurcation lesions treated with a biolimus A9 eluting dedicated stent: results from the prospective, multicenter DIVERGE trial (DES intervention for treating side branches effectively)
125Six-month clinical outcomes after placement of a dedicated bifurcation device: a patient-level pooled analysis of five post-marketing registries
126Use of a dedicated stent versus tubular stents for bifurcation lesions in a single center during primary or rescue angioplasty
127Usefulness of the index of microcirculatory resistance for invasively assessing coronary microvascular dysfunction in epicardial coronary artery with atherosclerosis
128Physiological assessment of intermediate coronary stenoses with instantaneous wave-free ratio, an adenosine-free pressure-derived index: results of a multi center international registry
129Comparison of fractional flow reserve versus instant wave-free ratio for assessment of coronary artery stenosis severity in routine practice
130Diagnostic performance of a novel index, the instantaneous wave-free ratio (iFR), for the detection of functionally significant coronary artery stenosis
131Functional assessment of coronary artery stenosis severity by contrast-induced submaximal hyperaemia
132No more need of inducing hyperaemia if baseline Pd/Pa ≥0.96: combined approach based on both real clinical data and computational fluid dynamics model
133Comparision of quantitative assessment of coronary lumen dimension by IVUS and multidetector computed tomography
134Imaging criteria of non-invasive coronary computed tomographic angiography versus invasive coronary angiography and IVUS detecting lesion specific ischaemia by fractional flow reserve
135IVUS characteristics in patients with intermediate coronary lesions and borderline fractional flow reserve measurements
136Optimal IVUS criteria and their accuracy for defining the functional significance of intermediate coronary stenoses: an international multicenter study
137Optimal IVUS criteria defining physiologic optimisation by the fractional flow reserve after DES implantation
138Comparative study in two institutions between IVUS and pressure wire in the assessment of intermediate lesions
139Paclitaxel-eluting balloon in primary PCI in Amsterdam (PAPPA): sustained safety and efficacy at 6-month follow-up
140Paclitaxel releasing balloon with an inert BTHC excipient: six-month results on 1063 patients of the international DELUX registry
141Drug-eluting balloon for de-novo coronary artery disease: incidence of late thrombosis in a clinical setting and in clinical trials
142One-year clinical outcomes of percutaneous treatment with drug-eluting balloons: results from a multicenter registry
143An optical coherence tomography follow-up study of percutaneous bifurcation interventions with drug-eluting balloons
145Pathological aetiology of early, late, very late, and very very late stent thrombosis in 367 autopsy cases: bare metal versus DES
147Long-term outcome of patients treated with very long overlapping stents: the importance of high pressure post-dilatation
151Six-month results of randomised study to assess the effect of thrombus aspiration on flow area in STEMI patients: an optical frequency domain imaging study (TROFI)
152Clinical impact of residual coronary thrombus after thrombus aspiration in STEMI patients undergoing PCI
153Safety and efficacy of intense antithrombotic treatment and PCI deferral in patients with large intracoronary thrombus: a comparison with an ad hoc interventional strategy
156Abluminal drug releasing DES show a similar extent of endothelialisation as compared to bare metal sents but protect the vasculature against imaging induced inflammation and microthrombi
158Very long-term results of a the VestaSync 2 trial with the novel polymer-free hydroxyapatite sirolimus-eluting stent
159Late results of the PAX A trial comparing a novel polymer-free paclitaxel-eluting stent to the first generation Taxus paclitaxel-eluting stent with durable polymer
161Two-year results of the PLATINUM small vessel trial: evaluation of a 2.25 mm platinum chromium everolimus-eluting stent in de novo coronary artery lesions
164Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary PCI for STEMI: an analysis of the antiplatelet therapy for reduction of myocardial damage during angioplasty-myocardial infarction (ARMYDA-6 MI) study
165Randomised trial to investigate the impact of cilostazol on the angiographic outcome of drug-eluting coronary stent: an angiographic analysis of CILON-T trial
166Transferring from clopidogrel loading dose to prasugrel loading dose in ACS patients: the TRIPLET trial
167Prasugrel 5 mg in low body weight patients results in similarly low rates of high on-treatment platelet reactivity as prasugrel 10 mg in higher body weight patients
168In-vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional quantitative coronary angiography, intravascular ultrasound and optical coherence tomography
171Assessment of safety and diagnostic efficacy in dual-axis rotational coronary angiography versus standard coronary angiography
172Identification of culprit plaques in ACS: a comparison of coronary computed tomography with invasive catheter angiography
173Cardiac magnetic resonance imaging unveils hidden myocardial damage that cannot be evaluated by echocardiography or electrocardiography in patients with chronically occluded coronary artery disease
174The clinical impact of the second generation everolimus-eluting stent compared to the first generation DES in diabetes mellitus patients: insights from a nation-wide coronary intervention register
176Comparison of neointimal coverage of diabetic and non-diabetic patients using optical coherence tomography at 8 months after everolimus-eluting stent implantation
178Is bifurcation angioplasty associated with adverse procedural and clinical outcomes in patients presenting with STEMI and primary PCI?
179Acute ischaemic complications of PCI and CABG: who should cover whom for coronary revascularisation?
181Prognostic value of presentation with STE-ACS versus NSTE-ACS in patients with acute occlusion of the left circumflex artery
182Impact of body mass index on mortality in patients with ACS: a report from the Swedish coronary angiography and angioplasty registry (SCAAR)
183Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy
184Haemodynamic changes acutely determined by primary PCI in STEMI patients assessed with a minimally invasive method
185Current trends and outcomes in patients suffering acute myocardial infarction with cardiogenic shock and requiring haemodynamic support with a temporary left ventricular assist device: a multicenter observational study
186Effect of intra aortic balloon counterpulsation support commenced before or after primary PCI in cardiogenic shock due to STEMI
187Low mortality following protocol-based early intervention for ischaemia and ventricular arrhythmia in STEMI
188Impact of intravascular ultrasound guided left main intervention with DES on 2-year clinical outcomes
190Better one-year survival in consecutive unprotected left main patients with cutting balloon pre-dilatation and IVUS guidance
191Two-year clinical outcome in patients with angiographically intermediate lesions with minimum lumen area less than 4 mm2 using intravascular ultrasound in non-proximal epicardial coronary artery
192A new mitochondrial permeability transition pore inhibitor for myocardial salvage in primary PCI: preliminary animal model data
193Do metabolic cytoprotectors used intracoronary during rescue PCI limit reperfusion myocardial injury in STEMI patients?
194First in vitro and in vivo results of an anti-human CD133-antibody covered stent in the porcine model
195Reduced inhibition of arterial smooth muscle cell proliferation and migration by endothelial progenitor cells compared to arterial endothelial cells under arterial flow
196Novel hydrophilic stents exhibit significant reduction of neointimal hyperplasia in a swine coronary artery model
197Concept and one-year in vivo preclinical data on a novel DES with amino acid-based bioabsorbable drug carrier mounted on an integrated delivery system
198Is new risk scoring system (SYNTAX score and EUROscore) improves the predictive ability in treating multivessel coronary disease?
199Angiographical lesion complexity score and in-hospital outcome after PCI: analysis from JCD-KICS multicenter registry
200The coronary artery bypass graft SYNTAX score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic (SYNTAX-LE MANS) sub-study
201Addition of two risk assessment scales for cardiac surgery (EuroSCORE and Society of Thoracic Surgeons) to the SYNTAX score to predict early mortality and major vascular events in patients with unprotected left main coronary disease
202Deleterious interaction between drug-eluting stent implantation and impaired platelet inhibition by clopidogrel following PCI
203The association of high inflammatory status and enhanced platelet reactivity has an incremental predictive value on the occurrence of peri-procedural myocardial infarction in patients undergoing PCI
204Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST-segment elevation ACS
205Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after PCI: systematic review and meta-analysis
206Cytochrome p450 2c19 polymorphism and risk of adverse clinical outcomes in coronary artery disease patients treated with clopidogrel: an updated meta-analysis
207CYP2C19 *2 and *17 allele have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after ACS
208Assessment of predictive factors that determines successful outcome of coronary chronic total occlusion revascularisation: experience from single center registry
209The procedural benefit of soft and tapered tip guidewire use as a first choice for chronic total occlusion revascularisation
210Effects of the IVUS-guided true lumen reentry method for recanalisation of chronic total occlusion
212Management of procedural complications related to PCI of chronic total occlusions via the retrograde approach: a Toyohashi experience
214Endothelial-dependent vasomotion in coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?
215Twelve-month clinical and angiographic results of the multicenter first-in-man BIOSOLVE-I study with the paclitaxel-eluting bioabsorbable magnesium scaffold
216Six and twelve-month greyscale and virtual histology IVUS results with the drug-eluting absorbable metal scaffold in the BIOSOLVE-I study
217Multi center, first-in-man evaluation of the myolimus-eluting bioresorbable coronary scaffold: 6-month clinical and imaging results
218Impact of vessel size on long-term clinical and multi-modality imaging outcomes after absorb everolimus-eluting bioresorbable vascular scaffold implantation
219The dynamic vascular response at the proximal and distal edges following implantation of the ABSORB everolimus eluting bioresorbable vascular scaffold as assessed with in vivo virtual histology intravascular ultrasound. A 2-year follow-up assessement from the first in man, ABSORB Cohort B Trial
220Do hypoglycemia and hyperglycemia have an equal effect on all-cause mortality across the spectrum of coronary artery disease manifestations?
221Correlation between renal function deterioration and glycemic variability, evaluated by a continuous glucose monitoring system, in patients undergoing PCI: preliminary results of a prospective study
222Correlation between diabetic retinopathy and the severity of coronary artery disease in Egyptian patients with type II diabetes mellitus
224Paclitaxel releasing balloon with an inert BTHC excipient: six-month results on the diabetics subgroup of the international DELUX registry
226Can the combined evaluation of IVUS parameters increase the accuracy for the diagnosis of functional significance of coronary artery stenosis?
227Functional SYNTAX score improves stratification of risk in patients with left main coronary artery disease
228Fractional flow reserve assessment for in-stent restenosis: providing the courage to defer target lesion revascularisation in angiographic significant lesions
229Long-term outcomes of fractional flow reserve-guided revascularisation strategy in patients with in-stent restenosis
230Long-term clinical outcome in patients with angiographically intermediate lesion of the coronary artery by-pass graft deferred on the basis of fractional flow reserve measurement
231Culprit lesion revascularisation versus complete revascularisation in acute myocardial infarction patients with multivessel disease undergoing PCI with DES
232Influence of single-vessel disease or multivessel disease with or without further revascularisation on mortality in patients with STEMI
233Comparison of clinical outcomes between infarct-related artery revascularisation only and multivessel revascularisation in patients with acute myocardial infarction and cardiogenic shock
234Primary multivessel intervention in acute myocardial infarction complicated by cardiogenic shock and resuscitated cardiac arrest
235Determinants of mortality in patients undergoing PCI in the setting of recent myocardial infarction complicatted by cardiogenic shock
236Practice of treatment of in-stent-stenosis in elective PCI in clinical practice in Europe: results of the EHS PCI registry
239Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after long DES implantation for coronary arteries
240Clinical outcomes of zotarolimus-eluting stents in patients with in-stent restenosis: a pooled analysis from the RESOLUTE All Comers and RESOLUTE International studies
242A randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: one-year clinical and eight-month angiographic outcome of the PRISON III trial
243Radial artery patency post percutaneous coronary intervention with intravenous Enoxaparin as procedural anticoagulant
244Long-term outcomes of percutaneous therapy for true bifurcation lesions treated with drug-eluting stents using the ‘shunt’ technique
245Long-term outcome of patients who underwent percutaneous coronary interventions (PCI) for stable and unstable acute coronary syndromes, including STEMI, in a regional hospital without on-site surgical back-up
246Evaluation of cardiac and cerebrovascular events in robotic coronary bypass surgery and hybrid revascularisation procedures
247Risk factors and risk score for prediction of contrast induced nephropathy in patients undergoing percutaneous coronary intervention
248Angiographic and procedural outcomes of percutaneous coronary intervention in patients with chronic coronary artery occlusion after intracoronary adenosine administration
249Angiographic and procedural outcomes percutaneous coronary intervention of patients with diabetes mellitus type 2 and chronic coronary artery occlusion after intracoronary administration adenosine
250Optimisation contractile function of left ventricle patients with chronic coronary artery occlusion after intracoronary administration adenosine
251A meta-analysis on the angiotensin-converting enzyme inhibitor effect in contrast-induced nephropathy
252Atorvastatin combining with probucol can reduce serum uric acid level during perioperative period of intervention
253Use of sedation-analgesia for the prevention of radial spasm. A randomised prospective study of two treatment strategies
256The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer
257Safety and feasibility of transradial versus transfemoral approaches for diagnostic coronary angiography during early phase of the learning curve
25810-Year clinical follow-up result of intracoronary radiation therapy with rhenium -188-diethylene triamine penta-acetic acid-filled balloon
259Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty
260Road to heart via hand. trans-radial arterial and upper extremity venous access for cardiac catheterization – The safety and feasibility study
262Brain natriuretic peptide as a predictor of prognosis in patients with unstable angina/non ST elevation myocardial infarction
263Efficacy of hydration with normal saline versus hydration with sodium bicarbonate in the prevention of CIN
264Trans-radial versus trans-femoral intervention for the treatment of coronary bifurcations: result from the the COBIS (COronary BIfurcation Stenting) registry
265Incorporation of balloon-cushion stenting technique in left main coronary artery bifurcation intervention
266Late clinical impact of postprocedural incomplete stent apposition and late acquired incomplete stent apposition after deployment of zotarolimus eluting stent or everolimus eluting stent
267Difference of Neointimal Appearance between Early and Late Restenosis after Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography
268Clinical impact of small-sized stent mal-apposition after stent implantation as detected by optical coherence tomography
269Repeated drug-eluting stent implantation for drug-eluting stent restenosis: first or second generation drug-eluting stent
274The comparison of lesion characteristics, angiographic and clinical outcome with sirolimus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent and everolimus-eluting stent after 12 months from implantation
275Three-year outcomes after the implantation of sirolimus-eluting stent, paclitaxel-eluting stent, and zotarolimus-eluting stent for coronary artery disease in real world
276Relationship between systemic levels of inflammatory biomarkers and coronary artery thin-capped fibroatheroma
277Impact of acute coronary syndrome on clinical outcomes in patients with coronary bifurcation lesions treated with drug-eluting stents
279Optical coherence tomography analysis for restenosis of everolimus-eluting stents in comparison with bare-metal stents and paclitaxel-eluting stents
280Impact of severity of diabetes on target lesion revascularisation in 5-year follow up after percutaneous coronary intervention with sirolimus eluting stents
281Index of microcirculatory resistance after elective percutaneous coronary intervention can predicts myocardial damage
283BEACON II - A prospective, multi-centre, observational, real-world registry to assess clinical outcomes of patients after treatment with the BioMatrixâ„¢ Stent
284Intravascular ultrasound results from the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study
285The DIVERGE trial (Drug Eluting Stent Intervention for Treating Side Branches Effectively): 3-year clinical results
286Optical coherence tomography assessment for biolimus-eluting stents and everolimus-eluting stents in the very early period
288Fixed, low dose unfractionated heparin for coronary angioplasty in acute coronary syndrome patients
290Prediction of future acute coronary syndrome in chest pain unit patients initially discharged with a negative evaluation
292Safety and efficacy of early head-up strategy after femoral artery sheath removal. Single-center randomized controlled study
293Direct aspiration of a large thrombus in acute myocardial infarction using a standard 6 Fr guide catheter
295Comparison of clinical characteristics, 1-year readmission rates, cost and mortality amongst patients undergoing percutaneous coronary intervention for stable angina, acute coronary syndromes and ST-elevation myocardial infarction
296Clinical characteristics and 1-year readmission rates, length of stay, cost and mortality in patients in men and women undergoing percutaneous coronary intervention
298Treatment of diabetic patients treated with a new generation drug-eluting stent: two years clinical outcomes
2992 years clinical outcome with a new generation drug eluting stent, a challenge in bifurcation treatment
300Influence of technique and anatomy on strut apposition in provisional stenting: insights from micro-CT and OCT
301Neointimal changes during an extended period after bare-metal stent implantation: insights from integrated backscatter intravascular ultrasound
302Statin use decreased short-term and long-term major adverse cardiac events in acute myocardial infarction in patients with renal insufficiency
303Percutaneous coronary intervention in patients with chronic total occlusion: CACTO (Complex Angioplasty & CTO Intervention Society - India) interventional data
305Short and mid-term outcomes of patients undergoing percutaneous replacement of aortic valve according to their renal function: a multicenter study
307Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced acute kidney injury in unselected patients undergoing TAVI
311Transcatheter left atrial appendage occlusion in atrial fibrillation: a 100 cases single centre experience
312Intraprocedural imaging of the left atrial appendage: implications for percutaneous closure with a device
313The role of intracardiac echocardiography in the management of left atrial appendage occlusion: three years experience
315Transcatheter percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation: The Belgian Registry
316One-year outcomes following left atrial appendage occlusion in high-risk patients with atrial fibrillation
317Differences in clinical outcomes based on adherence to valve sizing criteria using 2D echocardiography or 3D computed tomography in patients undergoing TAVI
318Echocardiographic predictors of the clinical efficacy of CoreValve implantation at one year in 984 patients from the Italian CoreValve registry
319Outcomes of post dilatation in patients with residual significant aortic regurgitation following valve implantation using two systems: a single center study
320Aortic regurgitation index defines severity of periprosthetic regurgitation and predicts outcome in patients after TAVI: a two-center experience
322Clinical outcomes in patients with residual aortic regurgitation after transcatheter heart valve implantation
324TAVI versus surgical aortic valve replacement for severe aortic stenosis: results from an intermediate risk propensity-matched population of the Italian OBSERVANT study
329Examination and comparison of European Health Technology Assessments (HTAs) performed on transcatheter aortic valve replacement
330Cost-effectiveness of TAVI in high-risk or inoperable patients with symptomatic aortic valve stenosis in Spain
332Transcatheter versus surgical aortic valve replacement in patients with symptomatic aortic stenosis at intermediate operative risk: cost analysis of a propensity matched cohort at one-year
334Percutaneous patent foramen ovale closure performed with only fluoroscopic monitoring: the San Raffaele experience
335Prevalence of pre and post-procedural arrhythmias in patients undergoing patent foramen ovale closure
338Preoperative multislice computerised tomography and transesophageal echocardiographic aortic annular sizing in TAVI
340Post-implantation shape of a device in relation to pre-procedural aortic anulus anatomy: an evaluation by MSCT
341Discordance in oversizing transcatheter aortic valves between echocardiography and multislice computed tomography scan: a reason for paravalvular aortic regurgitation and need for post-implant dilation?
342Adequate choice of the post dilatation balloon size in patients undergoing TAVI based on the computed tomography-scan analysis
343Can we reduce paravalvular aortic regurgitation after TAVI? A systematic analysis from a single center experience with a self-expanding bioprosthesis
347Percutaneous clousure of paravalvular aortic prosthetic regurgitation with a single type of device: clinical follow-up
349Severe decline in platelet count in patients treated by percutaneous aortic valve replacement is associated with a high in-hospital death rate
352Conduction disturbances after treatment of aortic stenosis with TAVI: the international multi-center ACCUTRACK conduction study
353Clinical impact of persistent left bundle branch block after revalving system implantation: insight from a multi center registry
355Comparison of pro- versus retrospectively-gated cardiac computed tomography protocols for pre-procedural assessment of aortic valve structures and of peripheral vessels prior to transcutaneous aortic valve implantation
356Aortic root geometry assessed by computed tomography reconstruction using a dedicated analysis tool in patients scheduled for transcatheter aortic valve replacement: mismatch of annulus and outflow tract dimensions
357Calcium distribution in the ascending aorta in patients undergoing TAVI: relevance to the transaortic approach
358Ascending aortic calcification: its distribution and clinical significance in patients undergoing TAVI
361Real-world European experience with percutaneous treatment of significant mitral regurgitation: demographics and procedural outcomes
363ACCESS-EUROPE phase II: trial design, preliminary demographics and procedural outcomes following percutaneous reduction of significant mitral regurgitation
365Percutaneous edge-to-edge repair in heart failure patients: early results from a real world setting
366One year follow-up in patients with severe mitral regurgitation and reduced ejection fraction after interventional edge-to-edge mitral valve repair
368Treatment of aortic stenosis with TAVI in a real world population: the international multi-center ADVANCE study
369Thirty-day outcomes in a 2700 patient international clinical registry with a second generation balloon expandable transcatheter heart valve using multiple access techniques
373Valve academic research consortium outcomes following TAVI with two available devices: 30-day and 1-year results from the Milan registry
380Incidence, predictors and implications of transfemoral TAVI related access site complications: a multicenter collaborative study
384Neurological complications after treatment of aortic stenosis with TAVI in a real-world population: the international multicenter ADVANCE study
387Balloon valvuloplasty as a bridge to TAVI: an attractive option for patients with aortic stenosis at very high-risk
388Standalone balloon aortic valvuloplasty: indications and outcomes from the UK in the transcatheter valve era
389Impact of gender on outcomes post balloon aortic valvuloplasty: result from the BRAVO (effect of BivaliRudin on Aortic Valve intervention Outcomes) study
390Comparison of mortality between minimal invasive and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis and high or intermediate risk for conventional surgery
391TAVI versus isolated surgical aortic valve replacement in a real-world population with severe aortic stenosis
392Impact of coronary artery disease according to Valve Academic Research Consortium outcomes following TAVI
393Echocardiographic results after TAVI: survey of 621 patients up to 4 years after implantation of two different prostheses types
394TAVI is associated with significant regression of left ventricular hypertrophy but not improvement in left ventricular function: a one-year follow-up study
399Impact of severe left ventricular systolic dysfunction on clinical and echocardiographic outcomes following TAVI for severe aortic stenosis
401A single type of device device: percutaneous closure of paravalvular mitral prosthetic regurgitation with clinical follow-up late
403Comparison of circular versus D-shape atrial element design for off-pump transapical mitral valved-stent implantation
404Treatment of functional mitral regurgitation by percutaneous mitral annuloplasty results in clinical benefit through 24 months
406Transapical aortic valve implantation: 6-month outcomes of a multi center study evaluating a second generation TAVI system
407Transapical aortic valve implantation using a new self-expandable bioprosthesis: pilot study mid-term outcomes in 50 patients
409Transcatheter aortic valve replacement for the treatment of degenerative bioprosthetic surgical valves: results of the Global Valve-in-Valve registry
411Correlation between cTCD and cTEE for detection of right to left shunt in patients with cerebrovascular stroke
412The contemporary outcome of fifty two consecutive surgical transcatheter valve implantation performed in one year
414Is female gender itself is a risk factor for development of severe pulmonary hypertension in secundum atrial septal defect?
415Transcatheter Aortic Valve Implantation (TAVI) associated atrioventricular heart block in self-expandable corevalve and balloon-expandable Edwards valves
416Comparison of rotational angiography with MSCT for evaluation of the aortic root for transcatheter aortic valve replacement
417The association of body mass index with clinical outcome in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation
419Image analysis of carotid plaque vasa vasorum by contrast enhanced ultrasonography: insights into the mechanisms of plaque enhancement and correlation with histological findings after carotid endarterectomy
420Correlation between coronary and carotid atherosclerotic plaque composition by IVUS virtual histology in patients with widespread atherosclerosis
421Open versus closed stent-cell design in carotid artery stenting: predicting geometrical and haemodynamic impact determination using patient-specific simulations
423Long-term outcome following carotid artery stenting with hybrid stent compared to closed-cell stent implantation
426Comparative analysis of retrieved particulate debris after superficial femoral atherectomy using three different atherectomy methods
427Angiographic and clinical efficacy of paclitaxel-coated versus uncoated balloon angioplasty for femoro-popliteal revascularisation: a meta-analysis of randomised trials
428Combined use of directional atherectomy and drug-eluting balloon for the treatment of heavy calcified femoro-popliteal lesions: one-year results from single center registry
429Six-month results of the BIOLUX P-I first-in-man study comparing a paclitaxel releasing balloon catheter versus an uncoated balloon catheter in femoro-popliteal lesions
430Patients with diabetes mellitus: clinical outcome at one-year in a large population of patients treated with Misago peripheral self-expanding stent system
431Percutaneous treatment in pulmonary embolism: comparison between intermediate and high-risk patients
433Thrombectomy for treatment of arterial limb ischaemia: report of a 2-phase prospective multicenter registry
434Percutaneous transluminal angioplasty versus primary stenting in infrapopliteal arteries in critical limb ischaemia
436Paclitaxel-eluting balloon for the treatment of below the knee arterial disease: one-year clinical and angiographic results from large single center registry
437Intensive survelliance followed by assisted intervention sustained long-term outcomes in patients with critical limb ischaemia
439Histopathological characterisation of renal arteries after radiofrequency catheter-based sympathetic denervation in a healthy porcine model
440A novel balloon catheter-based renal denervation shows reduction in norepinephrine kidney tissue concentration in a porcine model
441Percutaneous transluminal renal sympathetic denervation exerts a chronic effect on renal haemodynamics and plasma norepinephrine levels using a novel catheter for radiofrequency ablation: data from an animal study
442Safety and efficacy of a novel quadrapolar renal denervation catheter in patients with resistant hypertension: a first-in-man multicenter study
443Radiofrequency renal denervation for resistant hypertension: single institution efficacy and safety study
448Baseline systolic blood pressure seem to predict the extent of blood pressure reduction after renal sympathetic denervation in patients with resistant hypertension
449Pulse pressure predict coronary calcification better than other BP parameters in Women--WECAC (Women & Coronary Artery Calcium) Study
450Systolic blood pressure correlates to coronary calcification severity in women, subanalysis of WECAC (Women Coronary Artery Calcium) study
